Company Analysis
Sign in

Amylyx Pharmaceuticals, Inc. (AMLX)

Nasdaq: AMLX · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.4
◀ Past 5.1● Present 6.3▶ Future 4.8
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Report filedMar 3, 2026Mar 4, 2025Feb 22, 2024Mar 13, 2023Mar 31, 2022
Revenue087,371380,78622,230285
Cost of revenue05,95325,4412,993·
Research and development90,404104,084128,18793,45044,040
Selling, general and administrative62,887114,331188,356127,12838,933
Total costs and expenses153,291402,102341,984223,57182,973
Operating income-153,291-314,73138,802-201,341-82,688
Interest and investment income9,30213,80916,1554,29136
Other income (expense), net-700-1,214-660-551-51
Total non-operating income (expense)8,60212,59515,4953,740-5,243
Income before income taxes-144,689-302,13654,297-197,601-87,931
Income tax expense46-3935,026774·
Net income including non-controlling interests-144,735-301,74349,271-198,375-87,931
Net income-144,735-301,74349,271-198,375-87,931
Earnings per share, basic-1.53-4.430.73-3.39-13.35
Earnings per share, diluted-1.53-4.430.70-3.39-13.35
Weighted average shares, basic94,565,56768,142,15867,234,46558,495,5876,586,349
Weighted average shares, diluted94,565,56768,142,15869,991,34058,495,5876,586,349
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfGoodsAndServicesSold
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton AMLX · research, not advice